Pfizer raised its FY2026 revenue guidance midpoint by $500 million to a $60.5 billion to $62.5 billion range.
Berobenatide, Pfizer's ultra-long-acting monthly GLP-1 candidate, is being advanced toward a targeted first approval in 2028.
Pfizer expects to enter clinical development in 2026 with a fifth-generation adult pneumococcal vaccine candidate covering 35 serotypes.
Pfizer expects to start a pivotal trial in 2026 evaluating Nurtec as a treatment for chronic migraine.
Pfizer plans to release the clinical trial design in 2026 for an adjuvant atirmociclib study and start the trial by end-2026.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Pfizer Inc. and 4,900+ companies.